首页> 外文期刊>Plant Disease >Inducing Transient Mixed Chimerism for Allograft Survival Without Maintenance Immunosuppression With Combined Kidney and Bone Marrow Transplantation: Protocol Optimization
【24h】

Inducing Transient Mixed Chimerism for Allograft Survival Without Maintenance Immunosuppression With Combined Kidney and Bone Marrow Transplantation: Protocol Optimization

机译:在没有维持免疫抑制的情况下,肾脏和骨髓移植组合诱导同种异体移植存活的瞬态混合逆变:协议优化

获取原文
获取原文并翻译 | 示例
           

摘要

Background. Tolerance induction is an important goal in the field of organ transplantation. We have sequentially modified our conditioning regimen for induction of donor-specific tolerance in recipients of major histocompatibility complex-mismatched combined kidney and bone marrow transplantation (CKBMT). Methods. From December 2011 to May 2017, 8 major histocompatibility complex-mismatched patients received CKBMT. The initial conditioning regimen (protocol 1) consisted of cyclophosphamide (CP), rituximab, rabbit antithymocyte globulin, and thymic irradiation. Tacrolimus and steroids were used for the maintenance of immunosuppression (IS). Results. This regimen was complicated by transient acute kidney injury, which has been the major clinical feature of engraftment syndrome and side effects of CP, although one of 2 subjects successfully discontinued his IS for 14 months. The conditioning regimen was modified by reducing the CP dose and adding fludarabine (protocol 2). The final modification was reducing the fludarabine and rabbit antithymocyte globulin doses (protocol 3). Mixed chimerism, detected by the short tandem repeat method, was achieved transiently in all subjects for 3-20 weeks. Among the 3 subjects treated with protocol 2, IS was successfully discontinued for >35 months in one subject, but the other 2 subjects suffered from severe BK virus-associated nephritis. All 3 subjects treated with protocol 3 tolerated the protocol well and have successfully discontinued IS for >4-41 months. Interestingly, de novo donor-specific antibody was not detected in any subject during all the follow-up periods. Conclusions. Our clinical trial has shown that long-term renal allograft survival without maintenance IS can be achieved by induction of mixed chimerism following CKBMT.
机译:背景。耐受性诱导是器官移植领域的重要目标。我们顺序地修饰了我们的调理方案,用于诱导主要组织相容性复合肾和骨髓移植(CKBMT)的主要组织相容性复合物复合型肾脏和骨髓移植的接受者中的受体特异性耐受性。方法。从2011年12月到2017年5月,8个主要组织相容性复杂不匹配的患者接受了CKBMT。初始调理方案(方案1)由环磷酰胺(CP),Rituximab,兔抗肾小球球蛋白和胸腺辐射组成。他克莫司和类固醇用于维持免疫抑制(是)。结果。这种方案对短暂的急性肾损伤复杂化,这是植入综合征和CP副作用的主要临床特征,尽管2个受试者中的一个人成功停产他是14个月。通过减少Cp剂量和添加氟氮胺(方例2)来修饰调理方案。最终修饰在还原氟氮胺和兔抗腹细胞球蛋白剂量(方案3)。通过短串联重复方法检测到的混合斜切位学,在所有受试者中达到3-20周的瞬时达到。在用协议2治疗的3个受试者中,在一个受试者中成功停止> 35个月,但其他2个受试者患有严重的BK病毒相关的肾炎。用协议3治疗的所有3个受试者耐受方案良好,已成功停产> 4-41个月。有趣的是,在所有后续期间未在任何受试者中检测到De Novo供体特异性抗体。结论。我们的临床试验表明,通过诱导CKBMT后的混合逆变,可以实现无需维护的长期肾同种异体移植物存活。

著录项

  • 来源
    《Plant Disease》 |2020年第7期|共11页
  • 作者

  • 作者单位
  • 收录信息
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类 植物保护;
  • 关键词

相似文献

  • 外文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号